Doron received his Ph.D. from the Hebrew University Jerusalem in Pharmaceutical Sciences in 1987 and held a post doctoral position at the School of Pharmacy Ann-Arbor, Michigan in Prof Gordon Amidon's laboratories. In 1990 Dr Friedman was lecturer at the School of Pharmacy, Hebrew University of Jerusalem, and Jerusalem college of engineers and in 1991 joined the founding team of Pharmos Corp. as laboratory manager and later on as Director of Pharmaceutical Development of Pharmos Corp N.Y. At Pharmos, Dr. Friedman was responsible for New Chemical Entities development for the US and EU markets and for developing CMC file submissions to the FDA.
Dr. Friedman was co-founder at Foamix Ltd in 2003 (FOMX NASDAQ). Dr. Friedman served as Foamix CTO until 2008 where he managed joint pharmaceutical product development with major pharmaceutical companies. He was also responsible for CMC files and Pre-IND report submissions to the FDA, and scale-up and production of clinical and pre-marketing batches with sub contracts manufacturing. Since January 2009, Dr. Friedman was VP R&D of Lipocure Ltd, a Yissum Hebrew University Company that develops Injectable nano liposomal chemotherapy products, where he was responsible for tech transfers and bringing new products to clinical studies.
Dr. Friedman is the author of more than eighty (80) granted patents and patent families and over twenty (20) peer reviewed published articles and numerous presentations and patents in the area of Novel Drug Delivery Systems. He is a recognized expert in bio-pharmaceutics, drug delivery systems, pharmaceutical formulation, oral drug absorption and bio-availability and the inventor of Bouch&Lomb Lotemax™ formulation and topical foams marketed by Dr Reddy`s labs and Bayer Corp. Dr. Friedman's industrial experience entails managing pharmaceutical R&D, product development and design of pre-clinical and clinical studies. Dr. Friedman also holds extensive experience in developing innovative delivery solutions of water insoluble and amphiphilic pharmaceuticals. He has more than 25 years of experience.
Ran Frenkel is the Chief Development Operations Officer of Karyopharm Therapeutics Inc. - a clinical stage pharmaceutical company focused on novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. In this position Frenkel is responsible for development operations across the entire portfolio including Clinical Operations, Product Leadership, Medical Writing, Biostatistics and Data Management.
Ran has more than 20 years of experience in the international biopharmaceutical industry encompassing clinical, regulatory, business development and commercial operations activities. Prior to joining Karyopharm Ran Frenkel held a number of senior management roles in Europe, Israel and the United States, most recently as Managing Director EMEA for Clinipace Worldwide, an international clinical research organization, where he had responsibility for the overall management of the organization in Europe, the Middle East and Africa. Prior to joining Clinipace Worldwide, Mr. Frenkel established and managed the Israeli office of PFC Pharma Focus AG, which was acquired by Clinipace in 2011, and he held the position of Managing Director at Actelion Pharmaceuticals with responsibility for all science and business affairs of the company in Israel.
Ran holds a degree in Pharmacy from the Hebrew University in Jerusalem, Israel.
Adam Sohn is currently Vice President, US Regional Client Leader for Global Consulting at QuintilesIMS. During his 20+ year health care career, Adam has specialized in global commercial strategy development with particular attention to pricing and market access, launch strategy, and value driven models. Adam joined the Pricing and Market Access practice in 2004 and led the Center of Excellence for P&MA in the Americas from 2010-2015. During his tenure at QuintilesIMS, Adam has supported both large and small biopharmaceutical companies with the commercialization of niche and blockbuster drugs. His experience supporting corporations with portfolio and brand strategies extends five continents and has covered a myriad of therapeutic areas across primary and specialty care, oncology, vaccines and rare diseases. Prior to joining QuintilesIMS (previously IMS Consulting Group), Adam was an Associate equity analyst at CIBC World Markets covering the large and specialty pharmaceutical sectors and a healthcare management consultant at Ernst & Young Consulting, now Cap Gemini.
Adam holds an MBA from Columbia Business School and an undergraduate degree in Political Economy from Princeton University.